Relevant bibliographies by topics / Iodine-125 radioactive seeds / Journal articles
To see the other types of publications on this topic, follow the link: Iodine-125 radioactive seeds.

Journal articles on the topic 'Iodine-125 radioactive seeds'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 23 journal articles for your research on the topic 'Iodine-125 radioactive seeds.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Zhang, Wanfu, and Kaiyuan Luo. "Migration of Radioactive Iodine-125 Seeds: Case Report." Indian Journal of Surgery 75, no. 4 (June 19, 2012): 263–64. http://dx.doi.org/10.1007/s12262-012-0604-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Guo, Y., Y. Liu, Z. Li, D. Wang, Y. Du, J. Chen, and Z. Jin. "EUS-guided implantation of radioactive iodine-125 seeds in retroperitoneal metastatic adenocarcinoma." Endoscopy 41, S 02 (November 2009): E301. http://dx.doi.org/10.1055/s-0029-1214499.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Franca, Carlos A. S., Sergio L. Vieira, Antonio C. P. Carvalho, Antonio J. S. Bernabe, and Antonio B. R. Penna. "Radioactive seed migration after prostate brachytherapy with Iodine-125 using loose seeds versus stranded seeds." International braz j urol 35, no. 5 (October 2009): 573–80. http://dx.doi.org/10.1590/s1677-55382009000500009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Anglesio, Silvia, Elisa Calamia, Christian Fiandra, Francesca Romana Giglioli, Riccardo Ragona, Umberto Ricardi, and Roberto Ropolo. "Prostate Brachytherapy with Iodine-125 Seeds: Radiation Protection Issues." Tumori Journal 91, no. 4 (July 2005): 335–38. http://dx.doi.org/10.1177/030089160509100410.

Full text
Abstract:
Aims and background Brachytherapy for prostate cancer by means of permanently implanted 125 I sources is a well established procedure. An increasing number of patients all over the world are treated with this modality. When the technique was introduced at our institution, radiation protection issues relative to this technique were investigated in order to comply with international recommendations and national regulations. Particular attention was paid to the need for patient shielding after discharge from hospital. Methods The effective and equivalent doses to personnel related to implantation, the effective dose to patient relatives as computed by a developed algorithm, the air kerma strength values for the radioactive sources certified by the manufacturer compared with those measured by a well chamber, and the effectiveness of lead gloves in shielding the hands were evaluated. Results The effective dose to the bodies of personnel protected by a lead apron proved to be negligible. The mean equivalent doses to the physician's hands was 420 μSv for one implant; the technician's hands received 65 μSv. The mean air kerma rate measured at the anterior skin surface of the patient who had received an implant was 55 μGy/h (range, 10–115) and was negligible with lead protection. The measured and certified air kerma strength for 125I seeds in RAPID Strand corresponded within a margin of ± 5%. The measured attenuation by lead gloves in operative conditions was about 80%. We also defined the recommendations to be given to the patient at discharge. Conclusions The exposure risks related to brachytherapy with 125I to operators and public are limited. However, alternation of operators should be considered to minimize exposure. Patient-related measurements should verify the dose rate around the patient to evaluate the need for shielding and to define appropriate radiation protection recommendations.
APA, Harvard, Vancouver, ISO, and other styles
5

Jinna, Li, Liu Jingjia, Wang Hao, Qu Ang, Wang Junjie, and Zhao Yong. "The Anti-Tumor Effects of Iodine-125 Radioactive Seeds Radiation in Nasopharyngeal Carcinoma." Brachytherapy 13 (March 2014): S108. http://dx.doi.org/10.1016/j.brachy.2014.02.401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jinna, L., L. Jingjia, W. Hao, Q. Ang, Z. H. Yong, and W. Junjie. "EP-1911: The anti-tumor effects of iodine-125 radioactive seeds radiation in nasopharyngeal carcinoma." Radiotherapy and Oncology 111 (2014): S327. http://dx.doi.org/10.1016/s0167-8140(15)32029-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jin, Zhendong. "EUS-guided radioactive seeds implantation of iodine 125 in the retroperitoneal metastatic adenocarcinoma: a case report." Gastrointestinal Endoscopy 69, no. 2 (February 2009): S246—S247. http://dx.doi.org/10.1016/j.gie.2008.12.148.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Beniey, Michèle, Naomie Destrempes, Geneviève Coulombe, Mona El Khoury, and Edgard Nassif. "Use of Intraoperative Radioguidance in Recurrent Merkel Carcinoma." Case Reports in Surgery 2020 (June 19, 2020): 1–5. http://dx.doi.org/10.1155/2020/1789185.

Full text
Abstract:
Merkel cell carcinoma is a rapidly progressive nonmelanoma skin cancer with a high risk of recurrence. When recurrence occurs, it is associated with poor prognosis and there is a lack of guidelines for the management of such cases. This article describes a challenging case in which the innovative use of iodine-125 radioactive seeds permitted us to precisely identify and resect two nonpalpable recurrent nodules. The safety and accuracy of the surgical procedure were compromised by the presence of scar tissue following two past resections and two courses of radiotherapy. Radioactive seed localization is a well-known procedure in breast cancer, demonstrating potential for an extended application in other cancer types and in complex clinical situations.
APA, Harvard, Vancouver, ISO, and other styles
9

Dixon, Jordan, Bharti Jasra, Anita Ankola, Smita Sharma, and Haley Letter. "Bracketed Radioactive Seed Localization for Breast Conservation Surgery." American Surgeon 86, no. 2 (February 2020): 90–94. http://dx.doi.org/10.1177/000313482008600219.

Full text
Abstract:
We aimed to evaluate the surgical margin outcomes and re-excision rates in patients undergoing bracketed seed localization of biopsy-proven breast cancer detected on screening mammogram. After approval by our Institutional Review Board, we retrospectively identified patients who had undergone iodine-125 seed localized lumpectomy at our institution from January 2010 to June 2017 by one of two fellowship-trained breast surgeons. Of those patients, a subset of 25 patients were identified who had undergone bracketed seed localization, defined as two or more seeds used to delineate the radiographic borders of the area of concern. All patients had originally presented with calcifications identified on screening mammogram that were subsequently diagnosed as ductal carcinoma in situ and/or invasive ductal carcinoma by image-guided biopsy performed at our institution. Eight patients had one positive margin on final surgical pathology and required re-excision (32%). One patient was converted to mastectomy. Of the patients requiring re-excision, the average maximum linear extent of calcifications was 3.4 cm (SD 0.97), whereas it was 3.1 cm (SD 1.2) in patients with negative surgical margins ( P = 0.5). Bracketing calcifications with radioactive seeds can potentially allow more patients to undergo breast conservation surgery.
APA, Harvard, Vancouver, ISO, and other styles
10

Huang, M. W., J. Tan, D. Tong, J. Zhang, L. Zheng, G. Y. Yu, and J. G. Zhang. "The technical evaluation of postoperative iodine-125 radioactive seeds brachytherapy to treat malignant salivary gland tumours of palate." International Journal of Oral and Maxillofacial Surgery 38, no. 5 (May 2009): 440–41. http://dx.doi.org/10.1016/j.ijom.2009.03.159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Jackson, L., A. G. Bourke, F. Abdul Aziz, and D. Taylor. "Radioactive seed localisation to guide removal of impalpable lymph nodes (Radioguided Occult Lesion Localisation using Iodine-125 seeds, "ROLLIS")." Case Reports 2014, mar21 1 (March 22, 2014): bcr—2013–203267—bcr—2013–203267. http://dx.doi.org/10.1136/bcr-2013-203267.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Zhang, Wenchao, Jiawei Li, Ran Li, Ying Zhang, Mingyong Han, and Wei Ma. "Efficacy and safety of iodine-125 radioactive seeds brachytherapy for advanced non–small cell lung cancer—A meta-analysis." Brachytherapy 17, no. 2 (March 2018): 439–48. http://dx.doi.org/10.1016/j.brachy.2017.11.015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Vrancken Peeters, Marie-Jeanne TFD, Marieke Evelien Straver, Mila Donker, Claudette Loo, Gabe S. Sonke, Jelle Wesseling, and Emiel J. Rutgers. "Novel surgical technique to selectively remove metastatic axillary lymph nodes in breast cancer patients after neoadjuvant chemotherapy: The MARI procedure—Marking of the axilla with radioactive iodine seeds." Journal of Clinical Oncology 30, no. 27_suppl (September 20, 2012): 196. http://dx.doi.org/10.1200/jco.2012.30.27_suppl.196.

Full text
Abstract:
196 Background: An important benefit of neoadjuvant chemotherapy (NAC) is the increase in breast-conserving surgery. At present the response of axillary lymph node metastases to chemotherapy cannot be accurately assessed. Therefore axilla-conserving therapy is not yet a benefit. We aimed to assess a new surgical method to evaluate the axillary response: the MARI procedure, which stands for Marking of the Axillary lymph node with Radioactive Iodine seeds. Methods: Prior to NAC, proven tumor-positive axillary lymph nodes were marked with a Iodine-125 seed. After NAC, the marked lymph node was selectively removed with the use of a gamma-detection probe. A complementary axillary lymph node dissection was performed to assess whether pathological response in the marked node was indicative for the pathological response in the additional lymph nodes. Results: Tumor-positive axillary lymph nodes were successfully marked with Iodine-125 seeds in 68 patients. The marked lymph node (MARI-node) was surgically detected and selectively removed after NAC in all patients. The pathological response to chemotherapy in the MARI-node was indicative for the overall response in the additionally removed lymph nodes. In 47 patients the MARI-node contained residual disease (n=45 macrometastasis, n= 2 ITC). Thirty-five of them had macro- or micro metastases in the complementary axillary lymph node dissection specimen. In 21 patients the MARI-node was tumor negative. In 2 patients a macro metastasis was found in the additionally removed nodes, in 2 patients ITC were found and in the remaining 17 patients no residual tumor was found in the additionaly removed lymphnodes. (false negative rate of the MARI procedure: 9.5%). Conclusions: This study shows that marking and selectively removing metastatic lymph nodes after NAC is feasible. The tumor-response in the marked lymph node may be used to tailor further axillary treatment, and herewith enabling axilla-conserving surgery after neoadjuvant chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
14

Qi, Xiangjie, Zhaodong Li, Xiangguo Wang, Kexia Fang, Jian Shi, and Runming Sun. "Concurrent computed tomography-guided radioactive iodine-125 seeds percutaneous interstitial implantation and chemotherapy for treatment of cervical lymph node metastases." Journal of Cancer Research and Therapeutics 14, no. 7 (2018): 1163. http://dx.doi.org/10.4103/0973-1482.202896.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Gong, Maofeng, Jinhua Song, Xu He, Boxiang Zhao, and Jianping Gu. "Intraluminal Brachytherapy Using a Self-Expandable Stent Loaded With Linear Iodine-125 Seeds in a Patient With Reiterative Recurrence of Cancer-Associated Vein Obstruction: A Case Report With 3 Months of Follow-Up." Vascular and Endovascular Surgery 52, no. 6 (April 25, 2018): 463–68. http://dx.doi.org/10.1177/1538574418770324.

Full text
Abstract:
Cancer-associated vein obstruction (CAVO) is a common complication in oncological patients, but the effective therapeutic options are scant. We report a patient with reiterative recurrent CAVO who was successfully treated with intraluminal brachytherapy using a self-expandable stent loaded with linear radioactive iodine-125 seeds (RIS) strand. During follow-up, her clinical symptoms were well improved. Three-month imaging follow-up revealed satisfactory patency of the iliofemoral vein, and the stents combined with RIS strands performed well. No serious complications associated with the implantation of stent and RIS strands were documented in any of the sessions. Intraluminal brachytherapy using a self-expandable stent loaded with linear RIS may be a safe and effective option for CAVO as long as it includes not only blood flow restoration but also brachytherapy administration for cancer.
APA, Harvard, Vancouver, ISO, and other styles
16

Muraki, K., E. Ogo, H. Suefuji, H. Eto, C. Hattori, C. Tsuji, Y. Miyata, et al. "The Analysis of Radioactive Implant Migration in Patients Treated With Iodine-125 Seeds for Permanent Prostate Brachytherapy with Median Lobe Hyperplasia." International Journal of Radiation Oncology*Biology*Physics 99, no. 2 (October 2017): E255—E256. http://dx.doi.org/10.1016/j.ijrobp.2017.06.1214.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Ji, Zhe, Yuliang Jiang, Fuxin Guo, Ran Peng, Haitao Sun, Jinghong Fan, and Junjie Wang. "Clinical Outcome of CT Guided Radioactive Iodine-125 Seeds Implantation in the Treatment of Recurrent Head and Neck Tumors after External Beam Radiotherapy." Brachytherapy 17, no. 4 (July 2018): S45—S46. http://dx.doi.org/10.1016/j.brachy.2018.04.068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Zhang, Xin, and Jie Li. "Clinical Study of Computed Tomography-Guided Radioactive Iodine-125 Seeds Implantation by Fan-Shaped Distribution in Treatment of Pulmonary Malignancy Patients with Poor Lung Function." Brachytherapy 15 (May 2016): S151. http://dx.doi.org/10.1016/j.brachy.2016.04.269.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Lei, Guang-Yan. "Safety And Efficacy of Ct-guided Percutaneous and Transtracheal Iodine-125 Radioactive Seeds Implantation for Recurrence and Metastasis Of Esophageal Carcinoma in The Upper Posterior Mediastinum." Brachytherapy 17, no. 4 (July 2018): S60—S61. http://dx.doi.org/10.1016/j.brachy.2018.04.097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Adeyemi, Oludare Folajimi, and Rachid Mghari. "First brachytherapy treatment of prostate cancer in Nigeria using low dose rate radioactive iodine 125." African Journal of Urology 26, no. 1 (December 2020). http://dx.doi.org/10.1186/s12301-020-00098-7.

Full text
Abstract:
Abstract Background We report the first prostate brachytherapy in Nigeria, using low dose radioactive iodine 125 (I-125) permanent seeds implant. Case Presentation The low dose rate brachytherapy using I-125 implants was performed in a private clinic in the city of Benin, Edo state of Nigeria. This pilot study reports the case of the first two patients with prostate cancer. The patients were treated under spinal anesthesia using 2 ml of heavy bupibacaine which is equivalent to 10 mg of bupibacaine. Biopsy, total blood count, electrolytes, urea, creatinine, urinalysis, electrocardiogram, chest X-ray, prostate-specific antigen and bone scan were checked prior to the procedure. The first two prostate cancer patients who were in low risk category successfully received the treatment in the first day of the clinic’s operations. This paper describes the settings in which these clinical operations occurred, detailing the type of technology used, the clinical procedure and the obtained dose distribution. Conclusions The paper ends with discussing the overall cost of the investment and the challenges encountered as well as the perspectives of extending the brachytherapy practice to treat other cancer diseases, such as breast and genealogical cancers.
APA, Harvard, Vancouver, ISO, and other styles
21

Woulfe, P., F. J. Sullivan, L. Byrne, A. J. Doyle, W. Kam, M. Martyn, and S. O’Keeffe. "Optical fibre based real-time measurements during an LDR prostate brachytherapy implant simulation: using a 3D printed anthropomorphic phantom." Scientific Reports 11, no. 1 (May 27, 2021). http://dx.doi.org/10.1038/s41598-021-90880-6.

Full text
Abstract:
AbstractAn optical fibre sensor based on radioluminescence, using the scintillation material terbium doped gadolinium oxysulphide (Gd2O2S:Tb) is evaluated, using a 3D printed anthropomorphic phantom for applications in low dose-rate (LDR) prostate brachytherapy. The scintillation material is embedded in a 700 µm diameter cavity within a 1 mm plastic optical fibre that is fixed within a brachytherapy needle. The high spatial resolution dosimeter is used to measure the dose contribution from Iodine-125 (I-125) seeds. Initially, the effects of sterilisation on the sensors (1) repeatability, (2) response as a function of angle, and (3) response as a function of distance, are evaluated in a custom polymethyl methacrylate phantom. Results obtained in this study demonstrate that the output response of the sensor, pre- and post-sterilisation are within the acceptable measurement uncertainty ranging from a maximum standard deviation of 4.7% pre and 5.5% post respectively, indicating that the low temperature sterilisation process does not damage the sensor or reduce performance. Subsequently, an LDR brachytherapy plan reconstructed using the VariSeed treatment planning system, in an anthropomorphic 3D printed training phantom, was used to assess the suitability of the sensor for applications in LDR brachytherapy. This phantom was printed based on patient anatomy, with the volume and dimensions of the prostate designed to represent that of the patient. I-125 brachytherapy seeds, with an average activity of 0.410 mCi, were implanted into the prostate phantom under trans-rectal ultrasound guidance; following the same techniques as employed in clinical practice by an experienced radiation oncologist. This work has demonstrated that this sensor is capable of accurately identifying when radioactive I-125 sources are introduced into the prostate via a brachytherapy needle.
APA, Harvard, Vancouver, ISO, and other styles
22

Muraki, Koichiro, Chikayuki Hattori, Etsuyo Ogo, Hiroaki Suefuji, Hidehiro Eto, Chiyoko Tsuji, Yusaku Miyata, et al. "Analysis of radioactive implant migration in patients treated with iodine-125 seeds for permanent prostate brachytherapy with MRI-classified median lobe hyperplasia." Journal of Contemporary Brachytherapy, 2021. http://dx.doi.org/10.5114/jcb.2021.105944.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Ji, Zhe, Yuliang Jiang, Fuxin Guo, Ran Peng, Haitao Sun, Panfeng Wang, Jinghong Fan, and Junjie Wang. "Radiation-related Adverse Effects of CT-guided Implantation of 125I Seeds for Thoracic Recurrent and/or Metastatic Malignancy." Scientific Reports 9, no. 1 (October 15, 2019). http://dx.doi.org/10.1038/s41598-019-51458-5.

Full text
Abstract:
Abstract During radioactive Iodine-125 seed implantation (RISI), Iodine-125 radionuclide is implanted directly into a lesion and kills tumor cells by steadily emitting radiation. In our study, we analyzed the adverse effects of RISI for thoracic malignancy, and investigated the safety, dosage, and adverse effects of RISI for these cases. Between June 2007 and January 2018, 77 patients with thoracic recurrent and/or metastatic tumors who underwent CT-guided RISI were enrolled. Radiation-related adverse effects were analyzed, including pneumonia, esophagitis, hemorrhage, fistula, skin injury, heart injury, and spinal cord injury. We used the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 to evaluate adverse effects and analyzed the relationship between adverse effects and dosimetric parameters of organs at risk (OAR), including D0.1cc, D2cc, Dmean, and V20. The results of the study were as follows: The median follow-up period was 11 months. The median postoperative dose (D90) was 122 Gy (45.7–241.8 Gy). Three patients (3.9%) showed radiation pneumonitis of grade ≥2. Two patients (2.6%) showed radiation-induced esophagitis of grade ≥2. One patient (1.3%) showed an esophageal fistula. Two patients (2.6%) had a tracheal fistula. Five patients (6.5%) had radiation-related skin reactions. One patient (1.3%) reported chest wall pain, while three (3.9%) showed hemoptysis. No patients showed radiation myelitis or cardiotoxicity. The mean D2cc of organs at risk were 165.7 Gy (lung), 10.61 Gy (esophagus), 10.25 Gy (trachea), 18.07 Gy (blood vessel), 12.64 Gy (heart), 14.77 Gy (spinal cord), 17.47 Gy (skin). Dosimetric parameters, such as D0.1cc, D2cc and Dmean, were higher in patients with toxic reactions (above the upper limit of 95% confidence interval among the overall data). Chi-square test showed that skin D0.1cc > 600 Gy, D2cc > 500 Gy, and Dmean >90 Gy were associated with grade ≥2 radiation dermatitis (p < 0.05), but no clear dose-toxicity correlation was found in other OARs. So, we concluded that the overall incidence of toxicity and adverse effects from RISI for the treatment of thoracic tumors is low. The dose-toxicity characteristics have not been fully defined. Doses within the upper limit of the 95% confidence interval may be considered safe. This was a retrospective analysis, and follow-up period was minimal, indicating possible limitations of this study.
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography